PPD sells rights to inhibitors for $15M up front

PPD has gained a deal to sell its development and marketing rights to all dipeptidyl peptidase IV inhibitors to Takeda for $15 million up front along with unspecified milestones for any successful product development. PPD gained the rights in an earlier deal with Syrrx. Takeda bought Syrrx in March and renamed it Takeda San Diego.

- read this press release for more

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.